Zhenjun Tan, Brandon P Lucke-Wold, Aric F Logsdon, Ryan C Turner, Cong Tan, Xinlan Li, Jarin Hongpaison, Daniel L Alkon, James W Simpkins, Charles L Rosen, Jason D Huber
Blood-brain barrier (BBB) disruption and hemorrhagic transformation (HT) following ischemic/reperfusion injury contributes to post-stroke morbidity and mortality. Bryostatin, a potent protein kinase C (PKC) modulator, has shown promise in treating neurological injury. In the present study, we tested the hypothesis that administration of bryostatin would reduce BBB disruption and HT following acute ischemic stroke; thus, prolonging the time window for administering recombinant tissue plasminogen activator (r-tPA)...
October 5, 2015: European Journal of Pharmacology